Peptides: Tesamorelin, AOD9604, Tirzepatide (GLP-1 agonist) Tesamorelin is FDA-approved to reduce visceral adipose tissue (VAT) in HIV-associated lipodystrophy, but its fat-burning effects also appear in non-HIV populations AOD9604 is a modified fragment of human GH (176191) shown in animal and early human trials to enhance lipolysis without altering blood sugar or cortisol Tirzepatide , while technically a GLP-1/GIP agonist , is now frequently stacked with peptides in clinical practice to accelerate fat loss and appetite control
These nutrients help the liver break down and remove fat more efficiently, prevent fat buildup and promote steady energy levels
Patients start at 0.6 mg daily during week one
Send it back with the prepaid label and get results in just a few days
The ghk-cu peptide is naturally present in our bodies, particularly in plasma, saliva, and urine, though its concentration declines sharply with age